DK3043777T3 - Sublingual buprenorphinspray - Google Patents

Sublingual buprenorphinspray Download PDF

Info

Publication number
DK3043777T3
DK3043777T3 DK14843903.7T DK14843903T DK3043777T3 DK 3043777 T3 DK3043777 T3 DK 3043777T3 DK 14843903 T DK14843903 T DK 14843903T DK 3043777 T3 DK3043777 T3 DK 3043777T3
Authority
DK
Denmark
Prior art keywords
buprenorphinspray
sublingual
sublingual buprenorphinspray
Prior art date
Application number
DK14843903.7T
Other languages
English (en)
Inventor
Kiran P Amancha
Chandeshwari S Chilampalli
Venkat R Goskonda
Original Assignee
Fresh Cut Dev Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresh Cut Dev Llc filed Critical Fresh Cut Dev Llc
Application granted granted Critical
Publication of DK3043777T3 publication Critical patent/DK3043777T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK14843903.7T 2013-09-10 2014-08-26 Sublingual buprenorphinspray DK3043777T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361875837P 2013-09-10 2013-09-10
PCT/US2014/052699 WO2015038327A1 (en) 2013-09-10 2014-08-26 Sublingual buprenorphine spray

Publications (1)

Publication Number Publication Date
DK3043777T3 true DK3043777T3 (da) 2020-07-20

Family

ID=52625856

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14843903.7T DK3043777T3 (da) 2013-09-10 2014-08-26 Sublingual buprenorphinspray

Country Status (8)

Country Link
US (1) US9216175B2 (da)
EP (1) EP3043777B1 (da)
JP (1) JP2016529328A (da)
CA (1) CA2923811C (da)
DK (1) DK3043777T3 (da)
ES (1) ES2802976T3 (da)
HK (1) HK1225653A1 (da)
WO (1) WO2015038327A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020123764A (ru) 2014-04-04 2020-08-05 Интра-Селлулар Терапиз, Инк. Органические соединения
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
ES2864099T3 (es) * 2015-04-03 2021-10-13 Benuvia Therapeutics Llc Formulaciones de pulverización sublingual de sildenafilo
WO2016164158A1 (en) * 2015-04-09 2016-10-13 Insys Development Company, Inc. Ketorolac sublingual spray formulations
CA3003293A1 (en) * 2015-10-27 2017-05-04 Insys Development Company, Inc. Liquid buprenorphine formulations
PL3407888T3 (pl) 2016-01-26 2021-08-30 Intra-Cellular Therapies, Inc. Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania
EP3888656A1 (en) 2016-03-25 2021-10-06 Intra-Cellular Therapies, Inc. Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder
CA3033897C (en) * 2016-08-17 2024-03-26 Insys Development Company, Inc. Liquid naloxone spray
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
MX2021013640A (es) 2017-03-24 2022-08-31 Intra Cellular Therapies Inc Composiciones novedosas y metodos.
WO2019026085A1 (en) * 2017-08-04 2019-02-07 Alkem Laboratories Ltd. SUBLINGUAL FILM COMPOSITION
US20180193332A1 (en) * 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
CA3094204A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
CA3108553A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
JP7457000B2 (ja) 2018-08-31 2024-03-27 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
EP3993807A1 (en) * 2019-07-01 2022-05-11 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
WO2001097780A2 (en) 2000-06-22 2001-12-27 Pharmasol Ltd Pharmaceutical compositions comprising an opioid analgesic
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US7387623B2 (en) * 2002-08-21 2008-06-17 Pfizer Inc. Injectable pharmaceutical suspension in a two-chamber vial
US7084150B2 (en) * 2002-10-25 2006-08-01 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US7501113B2 (en) 2003-02-04 2009-03-10 Philip Morris Usa Inc. Aerosol formulations and aerosol delivery of buprenorphine
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US9522188B2 (en) 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US8486972B2 (en) * 2006-01-25 2013-07-16 Insys Therapeutics, Inc. Sublingual fentanyl spray
WO2007123955A2 (en) 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
US20100233257A1 (en) * 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
MX2009000745A (es) 2006-07-21 2009-04-16 Biodelivery Sciences Int Inc Dispositivos de suministro transmucosa con admision mejorada.
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20090270438A1 (en) 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB2461681A (en) * 2008-04-17 2010-01-13 Pharmasol Ltd Buprenorphine liquid spray formulation with solvent and antioxidant
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
CA2698749C (en) 2007-08-02 2017-05-23 Insys Therapeutics Inc. Sublingual fentanyl spray
MX2010010512A (es) 2008-03-26 2010-11-09 Alltranz Inc Formulaciones transdermicas de agonistas y antagonistas-agonistas de opiato que impiden el abuso.
CN102056578A (zh) 2008-06-23 2011-05-11 生物递送科学国际公司 多向粘膜给药装置及使用方法
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
JP5941038B2 (ja) * 2010-04-02 2016-06-29 ジネルバ ファーマシューティカルズ， インコーポレイティド 経皮送達可能なオピオイドプロドラッグ、乱用抵抗性組成物及びオピオイドプロドラッグを使用する方法

Also Published As

Publication number Publication date
JP2016529328A (ja) 2016-09-23
EP3043777A4 (en) 2017-08-02
ES2802976T3 (es) 2021-01-22
HK1225653A1 (zh) 2017-09-15
CA2923811C (en) 2021-07-27
WO2015038327A1 (en) 2015-03-19
CA2923811A1 (en) 2015-03-19
US20150071971A1 (en) 2015-03-12
US9216175B2 (en) 2015-12-22
EP3043777A1 (en) 2016-07-20
EP3043777B1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
DK3342773T3 (da) Syk-hæmmere
DK3043777T3 (da) Sublingual buprenorphinspray
DK3613453T3 (da) Fordamper
UY4298S (es) Carcasa
DK3077047T3 (da) Aramcholsalte
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
DK3052081T3 (da) Pastil
DK2946640T3 (da) Langmuir-probe
DK3071227T3 (da) Fiskevaccine
DE102013106534B8 (de) Chromatographiepipettenspitze
DE112014001252A5 (de) Aufbissschiene
DK2981168T3 (da) Laminitiskile
DK3086679T3 (da) Sportssko
FI10343U1 (fi) Mittateippi
FI10138U1 (fi) Kelkkateltta
ES1078715Y (es) Mosquitera
DE112014005422A5 (de) Friktionsfalschdrallaggregat
BR112016000501A2 (pt) Nalador
UY4342S (es) Carcasa
FI10396U1 (fi) Tielana
ES1100380Y (es) Trompo
ES1093505Y (es) Aerociclo
ES1096481Y (es) Ecofregona